CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FDA Biologics (BLA & Biosimilars)
Original article

CBER-Regulated Products: Shortages and Discontinuations

Neutral
AI Analysis

Summary

FDA CBER defines a product shortage as the inability of a CBER-regulated product to be commercially available in sufficient quantity to meet demand.

Importance:1/10
Sentiment:
0.00
CBERproduct shortagediscontinuationregulatory

Read the original article

Published by FDA Biologics (BLA & Biosimilars) on July 29, 2026 5:49 PM

Read Original